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Background: The goal of this report was to evaluate the efﬁcacy and tolerance of chemoradiotherapy in
elderly cervical cancer patients.
Methods: One hundred thirteen patients aged older than 75 years had been treated in Mackay Memorial
Hospital with Zubrod performance status 0e1. Patients were classiﬁed into three groups: Group 1 with
radiation less then 45 Gy for palliation or no radiotherapy, Group 2 with at least 45 Gy to whole pelvis
with or without brachytherapy, and Group 3 with completed radiotherapy with brachytherapy of 30 Gy
and concurrent chemotherapy. Toxicities were graded weekly according to National Cancer Institute
Common Toxicity Criteria version 3.0. Overall survival and progression-free survival were analyzed with
Kaplan-Meier method and compared by the log-rank test.
Result: About 30% of the patients had diabetes or hypertension or both. Only one case with adenocar-
cinoma was noted in Group 2. Higher ratio of Stage IV disease was noted in Group 1, but clinical stage is
not signiﬁcantly different in the three groups (p¼ 0.55). In Group 3, 52% patients completed six cycles of
cisplatin-based chemotherapy, but higher noncancer-related death ratio was noted. The 5-year actuarial
overall survival of Group 1, Group 2, and Group 3 is 11%, 27%, and 74%, respectively (p< 0.001). The
5-year progression-free survival of Group 1, Group 2, and Group 3 is 11%, 24%, 64%, respectively
(p¼ 0.003).
Conclusion: Chemoradiotherapy is effective and tolerable in elders with cervical cancers. Chemo-
radiotherapy should be considered in elderly patients with invasive cervical cancer.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Deﬁnitive radiotherapy (RT) is the primary treatment for
advanced cervical cancer. Even with appropriate doses, high inci-
dence of local pelvic recurrence and systemic failures had been
noted. Randomized trials form several cooperative groups were
published between 1999 and 2002, progression-free survival (PFS)
and overall survival (OS) had been improved by concurrent
cisplatin-based chemoradiotherapy and then RT alone1. Concurrent
RT and chemotherapy had become a standard for locally advanced
cervical cancer since 1999.
Although cervical cancer typically occurs in the ﬁfth and sixth
decades of life, less than 20% of patients are older than 75 years2.f Radiation Oncology, Mackay
ection 2, Taipei 104, Taiwan.
erest.
iwan Society of Geriatric EmergenOld aged patients’ tolerance may be compromised because of
their general performance status and comorbidities and general
concepts about short residual life. Therefore, how to optimally
manage such cases is a clinical dilemma.
We retrospectively reviewed patients aged 75 years or older
with good performance status treated in Mackay Memorial
Hospital since 1999e2006 and to analysis their survival status and
compliance of different treatment modality, we wish to get the
experience of treatment in this group of patients to provide better
management.2. Patients and Methods
2.1. Patient population
From January 1999 to June 2006, there were 1,283 cervical
cancer cases who had been treated with RT. One hundred thirteen
patients older than 75 years had been treated in Mackay Memorialcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
M.-H. Wu et al90Hospital with Zubrod performance status 0e1. After complete
history, physical examination, and laboratory studies, most patients
underwent cystoscopy and proctoscopy. The extent of workup and
radiographic studies were obtained.Table 1
The 113 patients’ characteristics
Group 1 Group 2 Group 3 p
n 29 53 31
Age (yr)
Median 80.02 81.15 77.68 0.74
Range 75e89 75e90 75e86
Medical Problems (%)
Diabetes 33 25 23 0.87
Hypertension 28 30 32
Others (CHF, arthritis, and so on) 10 15 19
Histology (%)
SCC 85 95 100 0.94
Ad-CA 0 3 0
Unknown 15 2 0
ECOG-PS (%)
0 30 55 40 0.23
1 70 45 65
Stage (%)
I 17 20 19 0.55
IIA 10 23 35
IIB 6 13 22
IIIA 0 2 3
IIIB 9 17 16
IVa 3 2 0
IVb 7 2 3
Unknown 3 21 02.2. Treatment
All patients had adequate bone marrow, renal function, and
hepatic function and were scheduled to take a combination of
external beam RT (EBRT) or EBRT with weekly intravenous
cisplatin chemotherapy. Megavoltage EBRT was delivered by
a linear accelerator (Clinac1800, Varian Associates, Inc., Palo Alto,
CA, USA) to target volumes, including the primary lesion and the
pelvic and common iliac lymph nodes. Paraaortic lymph nodes
were included if metastases were detected in the dissected nodes.
RT was delivered by an initial four-ﬁeld box technique followed by
a parallel-opposed technique at the time brachytherapy (BT) was
begun. A total of 45e50.4 Gy was prescribed in 25e28 equal
fractions to the isocenter by 15 MV X-ray at 320 cGy/min, ﬁve
daily fractions a week. A supplemental dose of 5.4e9 Gy was given
to the parametrium area when necessary. Periaortic node irradi-
ation may be given with 45 Gy of extended ﬁeld irradiation in
conjunction with whole pelvic radiation. High dose intracavitary
BT was given following the initial 30e40 Gy of EBRT to the whole
pelvis. It was delivered to Point A using a conventional prescrip-
tion at a total dose of 30 Gy in six fractions, twice a week, for
a minimum cumulative external and intracavitary dose of 85 Gy
and maximal dose of 90 Gy. We used Henschke shielded after-
loading applicators, set no. 084400 (Radiation Products Design,
Inc., Albertville, MN, USA) and iridium-192 for the isotope seed (Le
Petten, North Holland, The Netherlands). Treatment was planned
using the Plato Brachytherapy planning system version 14.2.4
(Nucletron International B.V., Veenendaal, The Netherlands). No
patient received more than 50.4 Gy in the whole pelvis. We
attempted to complete the entire course of RT within 8 weeks,
but treatment was withheld if the neutrophil count was lower
than 1,000 cells/dL or the platelet count was lower than 50,000
cells/dL.
Eligibility criteria for administration of chemotherapy included
a serum creatinine level lower than 1.5 mg/dL, absolute neutrophil
count higher than 1,500 cells/dL, and a platelet count higher than
100,000 cells/dL. Cisplatin (Bristol-Myers Squibb, Italy) was
administered beginning on Day 1 of RT at a dose of 40 mg/m2
weekly, no more than 70 mg per dose, up to 6 doses. Adequate
hydration and appropriate antiemetics were given before and after
the cisplatin. Cisplatin was withheld if the absolute neutrophil
count level was lower than 1,000 cells/mL, creatinine level higher
than 2.0 mg/dL, or platelet count lower than 75,000 cells/dL. It was
given at 70% of the initial dose if the creatinine level was
1.5e2.0 mg/dL, neutrophil count 1,000e1,500 cells/dL, or platelet
count 75,000e100,000 cells/dL. Patients were given transfusions
with packed red blood cells to maintain a hemoglobin level greater
than 10 g/L during concurrent chemoradiotherapy (CCRT).Chemotherapy (%)
0 100 100 0
1e3 9
4 12
5 27
6 52
Status
Death, n (%)
Cancer-unrelated death 48 60 26 0.009
No death 2 (14) 4 (13) 4 (50)
Ad-CA¼ adenocarcinoma; CHF¼ congestive heart failure; ECOG-PS¼ Eastern
Cooperative Oncology Group Performance Status; SCC¼ squamous cell carcinoma.2.3. Follow-up
After completion of treatment, patients received regular
follow-up every 1e2 months in the ﬁrst year, then every 3 months
subsequently. A pelvic examination and physical examination was
performed during each follow-up, whereas tumor markers
(squamous cell and carcinoembryonic antigens) were checked
every 3e6months and a radiographic examination (chest X-ray and
abdominopelvic computed tomography scan) was conducted every
6e12 months.2.4. Toxicity analysis
Chart review was used for toxicity analyses. Toxicities were
graded weekly according to National Cancer Institute Common
Toxicity Criteria version 3.0
2.5. Statistical analysis
Kaplan-Meier method was used for PFS and OS actuarial anal-
yses and compared by the log-rank test. We used the Student t test
to ﬁnd the signiﬁcance of between-group differences in treatment
groups. All datawere analyzed with the SPSS program forWindows
(Version 10.0.1, SPSS Inc., Chicago, IL, USA). Ninety-ﬁve percent
conﬁdence intervals for the proportions were calculated and are
mentioned in the text. A p value of 0.05 and less was considered
signiﬁcant, and only two-sided results with assumed equal vari-
ance were used. Intervals were determined from the date of the
diagnosis.
3. Results
The patients were classiﬁed within three groups: Group 1 with
radiation less then 45 Gy for palliation or no RT, Group 2 with at
least 45 Gy to whole pelvis with or without BT, and Group 3 with
completed RT with BT 30 Gy and CCRT. The median follow-up is
35 months (range: 1e101 months). The patient and tumor char-
acteristics of these three groups are summarized in Table 1. The
Concurrent Chemoradiotherapy Should be Given for Elderly Patients With Cervical Cancer With Good Performance Status 91mean age for these three groups is 80.02, 81.15, and 77.68 years,
respectively. About 30% of the patients had diabetes or hyperten-
sion or both. About 15e20% cases had other diseases, such as
arthritis, congestive heart disease, or chronic renal impairments.
Only one case with adenocarcinoma was noted in Group 2 in this
analysis. Because this study is a retrospective one, patients with no
pathological reports were noted in 15% cases in Group 1 and 2% in
Group 2. About 45e70% of patients were with performance status
one. Around 27e54% patients in the three groups were in early
stage and clinical stage was not signiﬁcantly different in the three
groups (p¼ 0.55). Higher Stage IV disease was noted in 10% of
Group 1. Fifty-two percent patients in Group 3 completed six cycles
of cisplatin-based chemotherapy. The death ratio is less for Group 3
who received CCRT. But higher noncancer-related death ratio was
noted. Then, we compared these three groups with the type of
treatment received, morbidity, and survival.Cu
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Fig. 1. Kaplan-Meier survival curves for (A) overall survival and (3.1. Outcome
The 5-year actuarial OS of Group 1, Group 2, and Group 3 is 11%,
27%, and 74%, respectively. The 5-year PFS of Group 1, Group 2, and
Group 3 is 11%, 24% 64%, respectively. The FFS and OS of the entire
group are shown graphically in Fig. 1. The mean and median
survivals of different groupswere summarized in Table 2. As seen in
Table 2, patient who had completed RT had better OS and PFS than
the patients who had no or incomplete RT. But who received CCRT
had the best OS and PFSwith amedian PFS of more than 90months.
3.2. Treatment sequelae
Table 3 summarizes the frequency and severity of acute
complication rates in the elderly receiving CCRT and RT alone.
Although Grade 0e1 acute genitourinary toxicity was common in)
s
ival
 1, Group 2 and
 log-rank).
, Group 2 and
, log-rank).
B) progression-free survival stratiﬁed by treatment received.
Table 2
Overall survival and disease-free survival (mean, median, conﬁdence interval, percentiles)
Group 1 Group 2 Group 3
5-yr overall survival (%) 11 27 74
Mean overall survival (mo) (95% CI) 26.52 (10.37e42.86) 34.70 (24.62e44.77) 77.36 (62.62e92.15)
Median overall survival (mo) (95% CI) 12.7 (0e27.04) 21.00 (14.62e27.38) 87.20 (52.51e121.89)
Percentiles for overall survival (%) (mo)
25 41.77 63 91
50 12.7 21 87.2
75 2.77 7.8 49.7
5-yr disease progression-free survival (%) 11 24 64
Mean progression-free survival (mo) (95% CI) 26.52 (10.37e42.68) 33.43 (23.72e43.15) 74.79 (58.76e90.91)
Median progression-free survival (mo) (95% CI) 12.7 (0e27.04) 21 (14.60e27.40) 91 (38.97e143.03)
Percentiles for progression-free survival (%) (mo)
25 41.77 46.13 Not reached
50 12.7 21 91
75 2.77 7.8 49
CI¼ conﬁdence interval.
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of acute toxicity (p¼ 0.167). Acute gastrointestinal (GI) (diarrhea
and abdominal cramping) and hematological (leukocytopenia or
thrombocytopenia) toxicities tended to be more signiﬁcant in
patients who received CCRT (p¼ 0.002 and p¼ 0.0001).
The chronic toxicity rates in these two groups are summarized
in Table 4. The overall Grade 2e3 complication rates were signiﬁ-
cantly higher in Group 3 who received CCRT for their cervical
cancers (p¼ 0.001 for GI toxicity, and p¼ 0.002 for genitourinary
toxicity).
4. Discussion
This study showed concurrent RT and chemotherapy was well
tolerable in old age group with good performance. Although higher
treatment-related acute and chronic toxicities had been noted,
elderly cervical cancers had a better overall outcome following
chemoradiotherapy, then radiation alone, or incomplete RT.
Although the invasive cancer incidence decreased by 47.8%
during 1995e2006 after the initiation of nationwide cervical cancer
screening, which was initiated in Taiwan in mid-19953, about 20%
women with cervical cancer do not receive treatment or receive
nonstandard therapies4. The elderly are more unwilling to get
treated because of poor general condition or no assistance for
medical care. Analysis in this study revealed that advanced stage
patients were more common in no treatment or incomplete RT
group than in the other groups. The current health service must
emphasize education for the elderly about cervical cancer
prevention and treatment while concentrating on screening.Table 3
The acute toxicity incidence related to radiotherapy (Group 2) and chemo-
radiotherapy (Group 3)
Grade Group 2 (%) Group 3 (%) p
Gastrointestinal 0 34.0 12.9 0.002
1 56.6 41.9
2 7.5 19.4
3 1.9 22.6
Genitourinary 0 79 77.4 0.167
1 18.9 9.7
2 1.9 9.7
Hematologic 0 90.1 48.4 0.0001
1 9.4 16.1
2 0 22.6
3 0 9.7Disease naturemay be different in different age group. Lau et al5
had reported that the proportion of nonsquamous cell carcinoma
was higher in patients 30 years or younger compared with in
patients older than 30 years (14/30, 46.7% vs. 10/30, 33.3%;
p¼ 0.001) in Taiwan. Poorer prognosis is more common in women
aged 30 years or younger with cervical cancer than in older women
with the disease. Goodheart et al6 had reported that elderly
patients were more likely to be diagnosed with nonsquamous
histologies. This histology may have impact on disease control. In
our study, only one case with adenocarcinoma in 113 cases was
noted. Therefore, we assumed that higher incidence with adeno-
carcinoma in elderly may be not true for Taiwanese. Several
molecular differences had been reported with elderly, such as low
prevalence of human papilloma virus DNA, low human papilloma
virus-16 DNA detection rate, more aneuploid tumors, and larger
proliferation indices7,8. Therefore, the tumor nature in elderly may
be different with young group; but the impact on survival in elderly
is unknown.
Delayed diagnosis in elderly will increase the disease stage; but
in age-adjusted treatment, results with RT were same as in young
patients that had been reported2. Concurrent medical problems in
elderly cervical cancer are higher than young patients. The inci-
dencewith hypertension, diabetes, and cardiovascular diseasewere
more than 30% and high incidence of death, more than 15%, because
of concurrent disease had also been noted in elders with cervical
cancer9. These conditions may compromise the administration of
treatment10. For RT alone, age is not associated with a higher rate of
acute or chronic sequelae for elderly. Comorbidity conditions
adversely impacted on the quality and delivery of RT in the elderly
group andmay help explain observed differences in outcome basedTable 4
The chronic toxicity incidence related to radiotherapy (Group 2) and chemo-
radiotherapy (Group 3)
Grade Group 2 (%) Group 3 (%) p
Gastrointestinal 0 92.5 58 0.001
1 7.6 22.3
2 0 16.1
3 3.2
Genitourinary 0 96.2 64.5 0.002
1 3.8 12.9
2 0 16.1
3 3.2
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and 50% noncancer-related death had been noted in patients who
underwent chemoradiotherapy. Because of signiﬁcant higher che-
moradiotherapy-related acute toxicities11, it is important to
monitor general condition for older patients during treatment.
Cisplatin had been suggested as standard agent for chemo-
radiotherapy in advanced cervical cancers12. Ciplatin had been
studied for elderly lung cancers13 or head and neck cancers14. The
response rate, toxicity, and survival were similar with age more
than 70 and age less than 70. Strategies to ameliorate toxicities
should be pursued in the elderly. In all of the trials, cisplatin-based
CCRT with RT was more effective at reducing the risk of death by
30e50%. Acute toxicities, principally neutropenia and GI, were
more commonwith chemoradiotherapy but were transient and the
rates of late complications (complications that persisted or
occurred for more than 60 days after the treatment) were similar15.
Although in this study, we did not compare elderly with younger
patients, only 3 cases (9.7%) received less than four cycles of
chemotherapy. The major causes of interruption were myelosup-
pression and Grade 3 GI toxicity. After aggressive ﬂuid support and
antibiotics use, more than 50% cases could complete chemotherapy.
For different radiation technique, intracavitary RT can improve
outcome in elderly had been reported in early days9. Elderly
women with cervical cancer tolerated BT well and had excellent
local disease-free and speciﬁc survival rates. Age did not inﬂuence
the effectiveness of BT in elderly patients and BT should be
considered whenever possible. But higher toxicity might be
increased if adding BT. There are only two cases who received
chemoradiotherapy without receiving BT in this study. We cannot
evaluate the role of BT in elderly when receiving chemo-
radiotherapy. Whether we can omit BT in elderly still needs further
study. The use of intensity-modulated RT (IMRT) in surgical-staged
cervical cancer had been proven with lower treatment-related
toxicities then conventional RT, but the use of IMRT in intact cervix
is still under investigation. Chen et al9 reported that tumor
response to EBRT was signiﬁcantly better for the older group than
for the younger group, chemoradiotherapy with combination of
IMRT for higher external radiation dose may have role in elderly
cervical cancers.
Because of low incidence for elderly cervical cancers, we
analyzed treatment results retrospectively. Bias in management
could not be avoided. The more experience in patients care, the
more patients can be cured with CCRT. OS and PFS could be
signiﬁcantly improved by chemoradiation with aggressive medical
care. Chemoradiotherapy should be considered in elderly patientswith invasive cervical cancer. Strategies to ameliorate toxicities
should be pursued in the elderly.
5. Conclusion
Although we noted that there were differences in the frequency
and severity of acute sequelae as a function of different treatment
for elderly patients, disease recurrence and death from cervical
cancer were more common in less treatment groups. Therefore,
aggressive management is indicated for elderly cervical cancers.
Chemoradiotherapy is effective and tolerable in this group. Elders
with cervical cancer should be encouraged to receive chemo-
radiotherapy aggressively.
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